Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.
Investor deep dive
Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation
Paradigm's drug developments sees growing market opportunities
Quick facts: Paradigm Biopharmaceuticals Ltd
Market Cap: $404 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...FOR OUR FULL DISCLAIMER CLICK HERE